Results 251 to 260 of about 6,958,201 (354)

Canine Distemper Virus in Mexico: A Risk Factor for Wildlife. [PDF]

Viruses
Macías-González J, Granado-Gil R, Mendoza-González L, Pedroza-Roldán C, Alonso-Morales R, Realpe-Quintero M.   +5 more
europepmc   +1 more source

In Vitro Modeling of Natural Killer Cell Cytotoxicity to Inform Personalized ALS Therapeutics

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Natural killer (NK) cells might contribute to motor neuron death in amyotrophic lateral sclerosis (ALS) through direct cytotoxicity, a process that could be inhibited with the FDA‐approved JAK/STAT pathway inhibitor, tofacitinib. This study aimed to verify that tofacitinib can suppress NK cell cytotoxicity, investigate if immune cell
Benjamin J. Murdock, Jihyun Park, Dae‐Gyu Jang, Bangyao Zhao, Samuel J. Teener, Ian F. Webber‐Davis, Lili Zhao, Eva L. Feldman, Stephen A. Goutman   +8 more
wiley   +1 more source

Monosodium glutamate: A hidden risk factor for obesity? [PDF]

Obes Rev
Kahe K, Laferrère B, Castellanos FX, Zhang Y, Mozaffarian D.   +4 more
europepmc   +1 more source

Asthma: A Risk Factor for Dental Caries?

, 1970
Manuel S. Thomas, Abhishek Parolia, M Kundabala   +2 more
openalex   +2 more sources

High‐Efficacy Treatment in Neuromyelitis Optica Specturm Disorder Patients With Seropositive AQP4 Antibodies—A Real‐World Study

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To compare the effectiveness of high‐efficacy treatments (HET) and low‐efficacy treatments (LET) in NMOSD patients with anti‐aquaporin‐4 antibodies (AQP4‐ab). Methods In this multi‐center study, we analyzed 183 AQP4‐ab seropositive NMOSD patients who received immunosuppressive treatments (IST).
Xiang Li, Binbin Xue, Jia Li, Dewei Xie, Juyuan Pan, Lanbing Zhu, Qiaowen Tong, Jing Lin, Xu Zhang, Junhui Xia, Jie Lin   +10 more
wiley   +1 more source

Serum Ferritin as a Risk Factor for Myocardial Infarction

, 1970
M Samiul Hafiz, MI Arslan, S Banarjee, M Obaidullah   +3 more
openalex   +2 more sources

A Validated Model to Predict Severe Weight Loss in Amyotrophic Lateral Sclerosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Severe weight loss in amyotrophic lateral sclerosis (ALS) is common, multifactorial, and associated with shortened survival. Using longitudinal weight data from over 6000 patients with ALS across three cohorts, we built an accelerated failure time model to predict the risk of future severe (≥ 10%) weight loss using five single‐timepoint ...
David G. Lester, Kevin Talbot, Martin R. Turner, Alexander G. Thompson, the Pooled Resource Open‐Access ALS Clinical Trials Consortium   +4 more
wiley   +1 more source

Preeclampsia as a Risk Factor of Postmenopausal Cardiovascular Disease: A Cross-Sectional Study. [PDF]

Clin Pract
Palmiero P, Caretto P, Amati F, Ciccone MM, Maiello M.   +4 more
europepmc   +1 more source

Real‐World Comparison of High‐Efficacy Versus Non‐High‐Efficacy Therapies in Multiple Sclerosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective The choice of the first disease modifying treatment (DMT) in multiple sclerosis (MS) is a topic of great interest, and whether high‐efficacy DMTs should be the first choice remains debated. We compared treatment outcomes (no evidence of disease activity [NEDA] and its components) between treatment‐naïve relapsing–remitting MS (RRMS ...
Sarmad Al‐Araji, Marcello Moccia, Alessia Bianchi, Charmaine Yam, Weaam Hamed, Suraya Mohamud, Alan J. Thompson, Frederik Barkhof, Ahmed T. Toosy, Olga Ciccarelli   +9 more
wiley   +1 more source